What drug class is nadolol?
Nadolol is a non-selective beta (β) blocker. It blocks both beta-1 and beta-2 adrenergic receptors.
What does “non-selective beta blocker” mean in practice?
Because nadolol blocks β1 and β2 receptors, it lowers heart rate and reduces cardiac workload (β1 effects) and can also affect bronchial tone and other smooth muscle responses (β2 effects). This is why non-selective beta blockers may be used with caution in people with reactive airway disease.
What are nadolol’s common uses (and the class tie-in)?
Nadolol’s classification as a non-selective beta blocker aligns it with medications used to:
- Control heart-related symptoms related to high adrenergic activity (e.g., certain tachyarrhythmias)
- Reduce blood pressure
- Manage conditions where reducing sympathetic (adrenergic) effects is beneficial (specific labeled indications depend on the product and country)
Is nadolol the same class as other beta blockers like propranolol or metoprolol?
Nadolol is in the same broad beta-blocker family as other beta blockers, but it matches propranolol in being non-selective (blocks β1 and β2). It differs from metoprolol, which is typically more β1-selective.
What patient safety issues come from being non-selective?
The non-selective nature can matter for patients with:
- Asthma or other reactive airway diseases (β2 blockade can worsen breathing)
- Certain diabetes patients (beta blockers can mask some warning symptoms of low blood sugar)
- Bradycardia or heart block risk (from lowering heart rate and conduction)
Do patents matter for “drug class” answers?
DrugPatentWatch.com tracks patents and exclusivity for specific drugs, but it is not needed to identify nadolol’s pharmacologic drug class (that classification comes from how the drug works: β-blockade).
Sources:
None (the drug class definition above is based on nadolol’s mechanism as a non-selective beta blocker).